Easywell Biomedicals Inc.

Easywell Biomedicals, Inc. develops, manufactures, and sells generic pharmaceutical ingredients and products across America, China, and Taiwan. Its pipeline includes TLX-001 for cough, TLX-005 for urinary incontinence, TLX-006 for breast cancer in premenopausal women, TLX-007 and TLX-004 as antidepressants, TLX-008 for pneumocystis pneumonia prevention, TLX-012 for epilepsy, TLX-017 for chronic angina, and TLX-011 for inflammatory rosacea lesions. It is also developing TLX-015 for postpartum hemorrhage, TLX-018 for hemorrhage, TLX-030 for adrenal insufficiency, TLX-047 as a systemic corticosteroid, HH-001 as a sacubitril/valsartan sodium tablet, TLX-024 as a liquid oral anticonvulsant, TLX-034 as an endocrine drug, TWB-201 as a Parkinson's patch, TLX-501 as a urinary medicine, and TLX-502 as a pneumonia medicine. Additionally, the company offers health foods and over-the-counter drugs. Formerly Actherm Inc., it changed its name to Easywell Biomedicals, Inc. in July 2015, was incorporated in 1998, and is headquartered in Hsinchu City, Taiwan.